Effects of cannabidiol (CBD) on regional cerebral blood flow - PubMed (original) (raw)
Clinical Trial
Effects of cannabidiol (CBD) on regional cerebral blood flow
José Alexandre de Souza Crippa et al. Neuropsychopharmacology. 2004 Feb.
Abstract
Animal and human studies have suggested that cannabidiol (CBD) may possess anxiolytic properties, but how these effects are mediated centrally is unknown. The aim of the present study was to investigate this using functional neuroimaging. Regional cerebral blood flow (rCBF) was measured at rest using (99m)Tc-ECD SPECT in 10 healthy male volunteers, randomly divided into two groups of five subjects. Each subject was studied on two occasions, 1 week apart. In the first session, subjects were given an oral dose of CBD (400 mg) or placebo, in a double-blind procedure. SPECT images were acquired 90 min after drug ingestion. The Visual Analogue Mood Scale was applied to assess subjective states. In the second session, the same procedure was performed using the drug that had not been administered in the previous session. Within-subject between-condition rCBF comparisons were performed using statistical parametric mapping (SPM). CBD significantly decreased subjective anxiety and increased mental sedation, while placebo did not induce significant changes. Assessment of brain regions where anxiolytic effects of CBD were predicted a priori revealed two voxel clusters of significantly decreased ECD uptake in the CBD relative to the placebo condition (p<0.001, uncorrected for multiple comparisons). These included a medial temporal cluster encompassing the left amygdala-hippocampal complex, extending into the hypothalamus, and a second cluster in the left posterior cingulate gyrus. There was also a cluster of greater activity with CBD than placebo in the left parahippocampal gyrus (p<0.001). These results suggest that CBD has anxiolytic properties, and that these effects are mediated by an action on limbic and paralimbic brain areas.
Similar articles
- Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.
Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Santos Filho A, Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JE. Crippa JA, et al. J Psychopharmacol. 2011 Jan;25(1):121-30. doi: 10.1177/0269881110379283. Epub 2010 Sep 9. J Psychopharmacol. 2011. PMID: 20829306 Clinical Trial. - Relationship between regional cerebral blood flow and separate symptom clusters of major depression: a single photon emission computed tomography study using statistical parametric mapping.
Périco CA, Skaf CR, Yamada A, Duran F, Buchpiguel CA, Castro CC, Soares JC, Busatto GF. Périco CA, et al. Neurosci Lett. 2005 Aug 26;384(3):265-70. doi: 10.1016/j.neulet.2005.04.088. Neurosci Lett. 2005. PMID: 15921853 Clinical Trial. - Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.
Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. Mandolini GM, et al. Epidemiol Psychiatr Sci. 2018 Aug;27(4):327-335. doi: 10.1017/S2045796018000239. Epub 2018 May 23. Epidemiol Psychiatr Sci. 2018. PMID: 29789034 Free PMC article. Review. - Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug.
Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, Zuardi AW. Schier AR, et al. Braz J Psychiatry. 2012 Jun;34 Suppl 1:S104-10. doi: 10.1590/s1516-44462012000500008. Braz J Psychiatry. 2012. PMID: 22729452 Review. English, Portuguese.
Cited by
- Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment.
Pérez R, Glaser T, Villegas C, Burgos V, Ulrich H, Paz C. Pérez R, et al. Life (Basel). 2022 Dec 15;12(12):2117. doi: 10.3390/life12122117. Life (Basel). 2022. PMID: 36556483 Free PMC article. Review. - Enhancing Endocannabinoid Control of Stress with Cannabidiol.
Henson JD, Vitetta L, Quezada M, Hall S. Henson JD, et al. J Clin Med. 2021 Dec 14;10(24):5852. doi: 10.3390/jcm10245852. J Clin Med. 2021. PMID: 34945148 Free PMC article. Review. - Hippocampal circuit dysfunction in psychosis.
Knight S, McCutcheon R, Dwir D, Grace AA, O'Daly O, McGuire P, Modinos G. Knight S, et al. Transl Psychiatry. 2022 Aug 25;12(1):344. doi: 10.1038/s41398-022-02115-5. Transl Psychiatry. 2022. PMID: 36008395 Free PMC article. Review. - Cannabis and schizophrenia spectrum disorders: a review of clinical studies.
Rodrigo C, Rajapakse S. Rodrigo C, et al. Indian J Psychol Med. 2009 Jul;31(2):62-70. doi: 10.4103/0253-7176.63575. Indian J Psychol Med. 2009. PMID: 21938097 Free PMC article. - Use of cannabinoid-based medicine among older residential care recipients diagnosed with dementia: study protocol for a double-blind randomised crossover trial.
Timler A, Bulsara C, Bulsara M, Vickery A, Smith J, Codde J. Timler A, et al. Trials. 2020 Feb 14;21(1):188. doi: 10.1186/s13063-020-4085-x. Trials. 2020. PMID: 32059690 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources